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Abstract 
Strokes and ischaemic heart disease are among the top ten causes of death in South Africa. Given 
that burden of disease, it is important to establish whether interventions aimed at preventing 
cardiovascular disease are not only effective, but cost effective too. Cost-effectiveness analyses 
compare interventions in terms of both their costs and consequences and are a useful tool for 
policymakers.  
Statins reduce the risk of cardiovascular events such as myocardial infarctions and strokes, by 
lowering low density lipoprotein cholesterol (LDL-C) concentrations. Several studies, mostly 
conducted in Europe or North America, have demonstrated that statins are cost effective, 
particularly when used to reduce the risk of further cardiovascular events in patients who already 
have cardiovascular disease (secondary prevention). Despite their widespread use, there are no 
published cost-effectiveness analyses of statins for the secondary prevention of cardiovascular 
disease in South Africa. There are also only limited local efficacy data from clinical trials and no 
costing data of cardiovascular events from a public healthcare sector perspective. 
There is some debate regarding the optimal statin dose. Some guidelines recommend increasing 
statin doses until target LDL-C concentrations are achieved, while others recommend prescribing 
statins at a fixed high dose without monitoring LDL-C. Monitoring LDL-C is relatively expensive 
compared to the cost of statins, but there is limited evidence that it might improve adherence.  
I compared the costs (from a provider perspective) and outcomes (life years), of increasing statin 
doses based on regular measurement of LDL-C concentrations, to achieve a target LDL-C 
concentration of <1.8 mmol/L; prescribing atorvastatin 80 mg without LDL-C monitoring; and the 
status quo, simvastatin 20 mg without LDL-C monitoring. I constructed a Markov model with annual 
cycles; a five-year timeline; starting age of 60 years; and the following health states: ≤1 year after 
first cardiovascular event, ≤1 year after subsequent cardiovascular event, >1 year after any 
cardiovascular event, and dead. I estimated transition probabilities using published literature. I 
estimated the costs of hospitalisation for myocardial infarctions, strokes, unstable angina pectoris 
and coronary revascularisation procedures using health services utilisation and expenditure data 
from a sample of patients at a public sector hospital. I discounted costs and outcomes at 3% per 
year; and explored alternative scenarios and timelines in sensitivity analyses. 
Atorvastatin 80 mg without LDL-C monitoring, was both the cheapest and most effective option over 
a five-year period. It remained the most effective option over a lifetime period, but with an 
incremental cost-effectiveness ratio (ICER) of $146.94 per life year gained relative to the status quo. 
Treat to target was as effective as atorvastatin 80 mg if I assumed adherence rates of 80% and 60% 
respectively, but with an ICER of $54 930.96. Treat to target would dominate atorvastin 80 mg only if 
the frequency of LDL-C monitoring was reduced from 3-monthly to 6-monthly until targets were 
reached, and the cost of LDL-C monitoring decreased by $9.25 (84%). 
Fixed-dose statin treatment without cholesterol monitoring is the most cost-effective option for 
providing statins for the secondary prevention of cardiovascular disease. The costs of regular LDL-C 
monitoring currently make a treat to target strategy unaffordable in our setting. These results might 
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Cardiovascular disease comprises several disorders of the heart and blood vessels, including heart 
attacks, angina and strokes. In South Africa, cardiovascular disease prevalence is increasing, and 
strokes and ischaemic heart disease are among the top ten causes of death.1,2 The recent South 
African National Health and Nutritional Examination Survey (SANHANES) that included 25 532 
individuals of all ages found the prevalence of self-reported heart disease was 6.1% (95% confidence 
interval (CI) 3.9 to 9.3) in those aged 55–64, and 4.4% (95% CI 2.6 to 7.1) in those aged 65 years or 
older. The prevalence of self-reported stroke was 6.1% (95% CI 4.0 to 9.3) in those aged 55–64, and 
9.1% (95% CI 5.2 to 15.5) in those aged 65 years or older.3 
High serum concentrations of low density lipoprotein cholesterol (LDL-C) increase the risk of 
cardiovascular disease.4,5 Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are a 
class of drugs that lower LDL-C concentrations by inhibiting cholesterol synthesis in the liver.6  
Reducing the risk of further events in patients who already have cardiovascular disease is known as 
secondary prevention. Owing to cost considerations, simvastatin is the statin that is currently 
recommended for secondary prevention of cardiovascular disease for most patients in South 
Africa.7,8 Atorvastatin is recommended when high statin doses are needed, as high dose simvastatin 
has a higher risk of causing muscle pain or weakness; and for co-administration with protease 
inhibitors (a class of antiretroviral drugs) in HIV patients, because of its lower potential for drug 
interactions.5  
Efficacy of statins in the secondary prevention of cardiovascular disease 
Clinical trials that compared statins with placebo demonstrated a significant benefit in terms of both 
the surrogate endpoint of reduction of LDL-C and cardiovascular events.9-15  More recent trials have 
focused on comparisons between different statins or different doses and have usually used 
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composite clinical endpoints comprising mortality, and cardiovascular events such as heart attacks 
and strokes.16-19 
The Cholesterol Treatment Trialists’ (CTT) collaboration conducted a meta-analysis of clinical trials 
using individual patient data.20 Based on five trials comparing high versus low dose statins for 
secondary prevention, they found higher doses were associated with an average further reduction in 
risk of major cardiovascular event (non-fatal myocardial infarction, coronary heart disease related 
death, stroke or coronary revascularisation procedure) of 28% (95% confidence interval 19 to 34) per 
1 mmol/L reduction in LDL cholesterol. They conclude that the greater the reduction in LDL-C (i.e. 
the higher the statin dose), the greater the clinical benefit.  
Cost-effectiveness of statins in the secondary prevention of cardiovascular disease 
Several studies have demonstrated that statin therapy is cost effective relative to placebo in patients 
with cardiovascular disease, assuming various willingness-to-pay thresholds.21-28 In line with recent 
clinical trials, recent economic evaluations have compared the costs and benefits of different statins 
or different doses. 29-36 
To our knowledge, no cost-effectiveness analyses of statins for secondary prevention of 
cardiovascular disease have been conducted in South Africa. 
Statin prescribing strategies 
The current European Society of Cardiology (ECS)/European Atherosclerosis Society (EAS) guidelines 
recommend starting statin treatment at a relatively low dose, monitoring LDL-C concentration 
regularly, and increasing statin dose if necessary to achieve LDL-C concentrations of below 
1.8 mmol/L for secondary prevention.37 Current South African Heart Association/Lipid and 
Atherosclerosis Society of Southern Africa guidelines recommend treating to achieve the ECS/EAS 
target, with measurement of LDL-C (along with high density lipoprotein cholesterol and triglyceride 
Cost-effectiveness of statin prescribing strategies for secondary prevention  Protocol 
3 
concentrations) at baseline, at four to eight weeks after treatment initiation or statin dose increase, 
and then six-monthly once stable.5 
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines and the National 
Institute for Health and Care Excellence (NICE) in the United Kingdom guidelines recommend 
atorvastatin 80 mg for secondary prevention unless patients have contra-indications to this drug or 
dose and measurement of LDL-C at baseline, then at 4-12 weeks (ACC/AHA guidelines) or three 
months (NICE guidelines), and then only as indicated clinically.38,39 
Local guidelines  
The current South African hospital and primary health care essential medicine list and standard 
treatment guidelines recommend use of a statin that reduces LDL-C by at least 25% for secondary 
prevention, and list simvastatin 10 mg as an example.7,8  
In Western Cape primary health care clinics, simvastatin 10 mg is available for secondary prevention, 
and simvastatin 20 mg is available for primary prevention for those with a ten-year risk of 
cardiovascular disease that is greater than 20%.40 In Western Cape hospitals, simvastatin 40 mg is 
available for prescription by physicians only, while doses greater than 40 mg may be prescribed at 
specialist lipid clinics only. Atorvastatin is available at lipid and antiretroviral clinics only.41 
Current local practice (status quo) 
Of 575 patients admitted to Groote Schuur Hospital for a cardiovascular event in 2012, 544 were 
discharged (the rest died during admission or absconded). Within the 544 patients who were eligible 
for secondary prevention, 385 (71%) had a statin prescribed within one month of admission. The 
most frequently prescribed statin was simvastatin 20 mg (91%), followed by simvastatin 10 mg (8%). 
Atorvastatin was prescribed in 1%. Sixty-six patients (12%) had cholesterol concentrations measured 
within one year of admission (excluding those done within one month of admission which are likely 
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to be screening for dyslipidaemia rather than monitoring response to treatment). Only 19% of those 
cholesterol concentrations were measured at outpatient clinics – the rest were done in wards or in 
the emergency department, so are most likely related to subsequent admissions for cardiovascular 
events, rather than monitoring. This analysis is restricted to Groote Schuur Hospital, and is limited by 
the fact that patients might have had cholesterol concentrations measured or statins prescribed at 
other facilities. However, it seems reasonable to assume that the vast majority of Groote Schuur 
Hospital patients eligible for secondary prevention received simvastatin 20 mg with very little 
cholesterol monitoring.    
Rationale 
Given the burden of cardiovascular disease in South Africa, it is important to establish whether 
interventions aimed at preventing cardiovascular disease are not only effective, but cost effective 
too. There is a paucity of data from our setting regarding the cost-effectiveness of statins in the 
secondary prevention of heart disease. The use of a Markov model allowed us to predict cost-
effectiveness of various statin delivery strategies using assumptions based on data from a variety of 
sources. Those estimates might be used to guide policy regarding secondary prevention of 
cardiovascular disease in South Africa. 
Aims 
In this economic evaluation we aimed to establish whether implementing frequent LDL-C monitoring 
and statin dose titration or using fixed doses of statins without LDL-C monitoring are cost effective 
options for providing statins for the secondary prevention of cardiovascular disease at Groote 
Schuur Hospital. 
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Objectives 
The objectives of the study were to compare the costs and clinical consequences (in terms of life 
years gained) of: 
• simvastatin 20 mg without monitoring LDL-C concentrations;
• atorvastatin 80 mg without monitoring LDL-C concentrations; and
• increasing statin doses (from simvastatin 20 mg to simvastatin 40 mg then atorvastatin 80 mg) if
necessary to achieve a target LDL-C concentration of <1.8 mmol/L.
Methods 
Study design 
We conducted a cost-effectiveness analysis. We compared the three statin prescribing strategies 
using incremental cost effectiveness ratios, and eliminated strategies that showed higher costs and 
lower effectiveness than an alternative strategy though absolute dominance.  
Perspective 
The analysis assessed the costs and consequences of the three statin prescribing strategies from a 
provider perspective. South Africa has a large private health sector, but over 80% of the population 
relies on the public sector for healthcare service provision.42 This analysis will focus on the public 
health sector, in particular that serving the Western Cape population. 
Interventions 
Status quo: simvastatin 20 mg without LDL-C monitoring 
The status quo comprised simvastatin 20 mg with a baseline lipogram only (to exclude patients with 
familial hypercholesterolaemia, who should not be treated according to the guidelines for secondary 
prevention patients), and no LDL-C monitoring on treatment. 
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LDL-C monitoring and statin dose titration 
In this scenario statin dose depended on LDL-C concentration. Patients had a baseline lipogram, and 
follow-up measurement of LDL-C every three months until they achieved treatment targets, and 
then every six months.  
Atorvastatin 80 mg without LDL-C monitoring 
In this scenario all patients received atorvastatin 80 mg. They had a baseline lipogram, no LDL-C 
monitoring on treatment.   
Analysis 
We used a Markov model for the analysis as they are well suited for assessing chronic conditions 
where events might recur.43 We developed a Markov model using TreeAge Pro software.44 The 
model had annual cycles and the following disease states: alive less than one year after first 
cardiovascular event; alive within one year of a subsequent heart attack; alive within one year of a 
subsequent stroke; alive within one year of a subsequent episode of unstable angina pectoris; alive 
within one year after a subsequent coronary revascularisation procedure; alive for more than one 
year after a cardiovascular event; and dead. We ran the model over a five-year timeline. We 
expressed costs in United States dollars and outcomes in life years gained. We discounted costs and 
outcomes at a rate of 3%. Because of the uncertainty of our baseline assumptions and to explore the 
generalisability of our results to other settings, we conducted threshold, one-way and multivariate 
sensitivity analyses.  
 




Figure 1. Simplified Markov model states and transitions.  
Dashed lines indicate the occurrence of a cardiovascular event. Cardiovascular events comprise 
myocardial infarction, unstable angina pectoris, stroke, or coronary revascularisation procedure. 
Transition probabilities 
Most published cost-effectiveness analyses of statins used efficacy data from clinical trials. However, 
no published clinical trial has directly compared the three proposed interventions. For that reason, 
we used an indirect approach to estimate efficacy: using the expected decrease in LDL-C 
concentration for each statin dose to estimate the effects of the statins on reducing the risks of 
cardiovascular events and death. This approach has been used in several previous statin cost-
effectiveness analyses.29,30,35,45 
We estimated the effect of each statin dose on LDL-C using a network meta-analysis by Naci et al.46 
We then used the relevant reduction in LDL-C to estimate the associated risk reduction of 
cardiovascular events and death using the meta-analyses conducted by the Cholesterol Treatment 
Alive ≤1 year after 
first cardiovascular 
event
Alive >1 year after 
cardiovascular 
event
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Trialists’ collaboration.20 We estimated the annual risks of cardiovascular events and cardiovascular 
death using the incidence rates seen in patients in the placebo arms of published clinical trials in 
secondary prevention populations.9,12,13 We used published South African mortality statistics to 
estimate non-cardiovascular mortality rates.47 We estimated the one-year outcomes after heart 
attacks, strokes, unstable angina pectoris and coronary revascularisation procedures using published 
data from various sources.17,33,48-51 
Costs 
We estimated the mean costs of treating cardiovascular events at Groote Schuur Hospital using an 
ingredients approach for diagnostic tests, drugs and surgical procedures and allocation using the 
patient day equivalent approach for hospital overhead costs.  
We identified a sample of patients admitted to Groote Schuur Hospital between 01 January 2012 
and 31 December 2013 using ICD10 codes for heart attack (I21.0, I21.1, I21.2, I21.3, I21.4, I21.9, 
I22.0, I22.1, I22.8), stroke (I60.0, I60.1, I60.2, I60.3, I60.4, I60.7, I60.8, I60.9, I61.0, I61.1, I61.2, I61.3, 
I61.4, I61.5, I61.8, I61.9, I62.0, I62.9, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.6, I63.8, I63.9, I64), 
and unstable angina pectoris (I20.0). We also identified patients who had cardiac revascularisation 
procedures such as coronary artery bypass grafts or percutaneous transluminal coronary 
angioplasty. We included all adult patients (at least 18 years old) with relevant diagnoses or 
procedures who were admitted for at least one night. We included all relevant admission periods, so 
some patients had more than one eligible admission.  
We used all admissions to estimate mean utilisation of health services according to admission 
diagnosis, but used 2012 prices to estimate mean costs. We identified all the laboratory tests, and 
diagnostic and surgical procedures done, and the drugs and blood products given during each 
eligible admission period. We restricted the tests, products and procedures to those related to 
treating the cardiovascular event. We obtained the prices paid for laboratory tests, drugs and blood 
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products from hospital expenditure records. We used Uniform Patient Fee Schedule prices for 
diagnostic procedures, such as x-rays, CT scans and ECGs, and surgical procedures.52 Those fees are 
the prices to be paid by private patients at public sector facilities, and include staff, consumable and 
overhead costs for the procedures.  
We calculated overall hospital overhead costs such as utilities (water, electricity, sewerage), 
catering, housekeeping, security, hospital management and administrative staff salaries, doctor 
salaries, and general maintenance using routine hospital accounting data. We used the approach 
suggested by Barron and Monitcelli to calculate a patient day equivalent: we added all of the 
inpatient days, half of the day cases and one third of the outpatient visits for the hospital over the 
time period.53 We divided the total costs by the patient day equivalent to estimate a mean cost per 
patient day equivalent for the hospital. We calculated mean lengths of stay according to admission 
diagnosis using the patient sample. We multiplied the cost per patient day equivalent by the mean 
lengths of stay to calculate mean hospital overhead costs for each type of cardiovascular event. 
We used a similar method to allocate ward costs, which comprised consumables, nurses’ salaries, 
and certain ‘ward stock’ drug costs which are allocated by ward, rather than to specific patients. 
Ethical considerations 
We conducted the study in accordance with the Declaration of Helsinki 2008 and the South African 
Department of Health Good Clinical Practice guidelines.54,55 
We used only anonymous patient identifiers (hospital numbers) to link patient data from various 
sources such as hospital, laboratory and pharmacy records. We stored data securely on a password-
protected laptop. We did not perform any interventions on patients for the purpose of this analysis 
and we did not seek any information directly from patients. We therefore did not seek informed 
consent from patients.  
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The University of Cape Town Faculty of Health Sciences Human Research Ethics Committee 
approved the study (reference number: 146/2014, Appendix 1) and the Groote Schuur Hospital 
superintendent granted permission for data collection at Groote Schuur Hospital. 
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Introduction 
In order to allocate scarce resources, healthcare policy makers must know both the efficacy and 
cost-effectiveness of strategies to prevent or treat diseases. Cost-effectiveness analyses compare 
interventions in terms of both their costs and consequences and assess their cost-effectiveness, 
relative to willingness-to-pay thresholds. However, they can’t assess affordability, so must be 
interpreted in terms of the overall impact of the interventions on finite budgets. They are a useful 
tool for policy-makers though, and are becoming increasingly expected, if not demanded, steps in 
drug approval processes in many countries. South Africa published guidelines for voluntary 
pharmacoeconomic evaluations in 2013.1 
Statins are a class of drug that reduce the risk of cardiovascular events such as myocardial infarctions 
(heart attacks) and strokes by lowering blood cholesterol concentrations. They have proven efficacy, 
and many studies (mostly conducted in Europe or North America), have shown them to be a cost 
effective intervention, particularly for the secondary prevention of cardiovascular events (that is the 
prevention of further events in patients with existing cardiovascular disease). 
This literature review summarises the prevalence of cardiovascular disease in South Africa, describes 
previously published cost effectiveness analyses of statins, particularly with respect to the methods 
used, and also discusses relevant data that were used to inform my cost-effectiveness analysis of 
three strategies for prescribing statins for the secondary prevention of cardiovascular disease from a 
South African public sector perspective. 
Objectives 
The objectives of this literature review were: 
1. To describe the current epidemiology of cardiovascular disease in South Africa;




2. To describe the current available evidence for the benefits of atorvastatin and simvastatin in the 
secondary prevention of cardiovascular disease; 
3. To describe the current available evidence regarding the cost-effectiveness of statins in the 
secondary prevention of cardiovascular disease;  
4. To summarise important methodological considerations for the conduct of a cost-effectiveness 
analysis; 
5. To summarise relevant efficacy data to inform my cost effectiveness analysis; and 
6. To summarise relevant costing data to inform my cost effectiveness analysis. 
Cardiovascular disease in South Africa 
Data regarding the incidence of cardiovascular diseases in South Africa are limited. Several surveys 
have estimated the prevalence of heart disease (including previous myocardial infarctions) and 
previous strokes using patient self-report. The South African National Health and Nutrition 
Examination Survey (SANHANES) was a cross-sectional survey that was representative of the whole 
South African population, and took place in 2012.2 Overall 25 532 people participated in the survey, 
which comprised an interview, physical examination and measurement of certain disease 
biomarkers (such as cholesterol concentration). The prevalence of self-reported heart disease was 
6.1% (95% confidence interval (CI) 3.9 to 9.3) in those aged 55–64, and 4.4% (95% CI 2.6 to 7.1) in 
those aged 65 years or older. The prevalence of self-reported stroke was 6.1% (95% CI 4.0 to 9.3) in 
those aged 55–64, and 9.1% (95% CI 5.2 to 15.5) in those aged 65 years or older. Phaswana-Mufuya 
et al conducted a national cross-sectional survey among people aged 50 years or older in 2008.3 In 
their sample of 3 840 people they found a lower prevalence of self-reported stroke (4.0%), and a 
prevalence of self-reported angina of 5.2%. Carrillo-Larco et al reported the prevalence of high 
cardiovascular risk in ten countries, including a sample of 691 people from an urban area in Cape 
Town, who were surveyed in 2008.4 In the Cape Town sample the self-reported prevalence of heart 
disease or previous heart attack was 1.5% (95% CI 0.4 to 5.5) in men younger than 50 years; 4.9% 
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(95% CI 3.0 to 8.6) in women younger than 60 years; 7.2% (95% CI 3.9 to 12.7) in men 50 years or 
older; and 12.9% (95% CI 7.9 to 20.3) in women 60 years or older. The self-reported prevalence of 
previous stroke was 1.0% (95% CI 0.2 to 6.0) in men younger than 50 years; 5.0% (95% CI 2.8 to 8.6) 
in women younger than 60 years; 7.3% (95% CI 4.3 to 12.1) in men 50 years or older; and 1.8% (95% 
CI 0.5 to 6.4) in women 60 years or older.  
The Global Burden of Disease 2013 study listed stroke as the sixth largest cause of life lost in South 
Africa (after HIV/AIDS, lower respiratory tract infections, tuberculosis, diarrhoea, and violence); and 
ischaemic heart disease as the eighth largest (after road accidents).5  
Statins for the secondary prevention of cardiovascular disease: 
efficacy 
Background: statin drugs 
High serum low density lipoprotein cholesterol (LDL-C) concentrations increase the risk of 
cardiovascular disease. Statins (HMG CoA reductase inhibitors) reduce LDL-C concentrations by 
inhibiting cholesterol synthesis in the liver.6 Several trials have demonstrated that statins have a 
significant benefit over placebo or no treatment, in terms of reducing LDL-C concentrations, and 
reducing the risk of clinical outcomes such as death, stroke or myocardial infarctions. The benefits of 
statins have been shown both in patients with raised LDL-C concentrations and those with normal 
LDL-C concentrations.7-9 
Patients who have already experienced a cardiovascular event are at increased risk for subsequent 
events, so local and international guidelines agree that they should receive statins (unless they have 
contraindications). Some guidelines recommend prescribing a relatively low dose statin at first, with 
regular LDL-C monitoring, and then increasing the dose if necessary to achieve a target LDL-C 
concentration.10,11 Others suggest prescribing a relatively high dose statin, at a fixed dose.12,13 




Based on current local and international guidelines and local practice, my cost effectiveness analysis 
compared simvastatin 20 mg (the status quo), atorvastatin 80 mg, and increasing statin doses (from 
simvastatin 20 mg to simvastatin 40 mg, then atorvastatin 80 mg) based on regular measurement of 
LDL-C concentrations, to achieve a target LDL-C concentration of <1.8 mmol/L. 
Search strategy: efficacy of atorvastatin and simvastatin for the secondary prevention 
of cardiovascular disease 
I conducted a Pubmed search using the following search terms: ‘statins’, ‘efficacy’, and 
‘cardiovascular’, restricted to randomised controlled trials. 
The full search details were: 
(("hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological Action] OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl-coa"[All 
Fields] AND "reductase"[All Fields] AND "inhibitors"[All Fields]) OR "hydroxymethylglutaryl-coa 
reductase inhibitors"[All Fields] OR "statins"[All Fields]) AND efficacy[All Fields] AND ("cardiovascular 
system"[MeSH Terms] OR ("cardiovascular"[All Fields] AND "system"[All Fields]) OR "cardiovascular 
system"[All Fields] OR "cardiovascular"[All Fields])) AND (Randomized Controlled Trial[ptyp] OR 
Clinical Trial[ptyp])  
Inclusion criteria 
• Types of studies: randomised controlled trials. 
• Population: adults with a history of cardiovascular disease (eligible for statins for secondary 
prevention of cardiovascular disease). 
• Interventions: atorvastatin or simvastatin (fixed doses or treat to target strategy). 
• Comparators: placebo, atorvastatin, simvastatin, treat to target strategy (involving any 
statins or doses) or placebo. 




• Outcomes: change in LDL-C or incidence of cardiovascular events. 
• Language: full article available in English. 
Results  
The search identified 404 potential studies. Additional searches including various combinations of 
the terms above as well as ‘simvastatin’, ‘atorvastatin’, ‘secondary prevention’, ‘low density 
lipoprotein’, and ‘target’ identified one additional placebo-controlled trial. Eleven studies met the 
eligibility criteria.  
Description of eligible studies 
No trial simultaneously compared atorvastatin 80 mg, simvastatin 20 mg and a treat to target LDL-C 
concentration strategy. No trial compared a fixed dose of either atorvastatin or simvastatin with a 
treat to target strategy. 
Five studies compared either simvastatin or atorvastatin with placebo or usual care. Three studies 
compared higher doses of either drug with lower doses of the same drug. 
The Scandinavian Simvastatin Survival Study (4S) compared simvastatin to placebo in 4 444 patients 
with angina pectoris or myocardial infarction.7 Simvastatin dose was increased if necessary to 
achieve a target LDL-C concentration of <3.0 mmol/L and median follow up was 5.4 years. They 
reported a relative risk of death of 0.7 (95% confidence interval 0.58 to 0.85). The A to Z trial 
compared simvastatin 40 mg, increased to 80 mg after one month, with placebo for four months, 
followed by simvastatin 20 mg in 4 497 patients who had an acute coronary syndrome event.14 They 
reported a hazard ratio for cardiovascular death, non-fatal myocardial infarction, acute coronary 
syndrome or stroke of 0.84 (95% confidence interval 0.76 to 1.04) after two years of follow up. The 
SEARCH trial compared simvastatin 80 mg and simvastatin 20 mg in 12 064 patients who had a 
myocardial infarction.15 They reported a relative risk of coronary death, MI, stroke of 




revascularisation procedure of 0.94 (95% confidence interval 0.88 to 1.01) after a median of 6.7 
years of follow up. 
The Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study 
compared atorvastatin 80 mg to placebo in 3 086 patients with unstable angina pectoris or non-Q-
wave myocardial infarction.15 The study duration was 16 weeks. They reported a relative risk of 
death, non-fatal MI, resuscitated cardiac arrest or recurrent myocardial ishaemia of 0.84 (95% 
confidence interval 0.70 to 1.00). The Stroke Prevention by Aggressive Reduction in Cholesterol 
Levels (SPARCL) study compared atorvastatin 80 mg to placebo in 4 731 patients with a stroke or 
transient ischaemic attack.16 Median duration of follow up was 4.9 years. The hazard ratio for stroke 
was 0.80 (95% confidence interval 0.69 to 0.92). The GREek Atorvastatin and Coronary-heart-disease 
Evaluation (GREACE) study compared atorvastatin to usual care in 1 600 patients with coronary 
heart disease.17 Atorvastatin dose was increased from 10 mg to a maximum of 80 mg if necessary to 
achieve a target LDL-C concentration of <2.6 mmol/L and 86% of the usual care patients received no 
cholesterol-lowering drugs. Mean duration of follow up was three years. The relative risk for death 
or coronary event was 0.49 (95% confidence interval 0.27 to 0.73). The Aggressive Lipid Lowering 
Initiation Abates New Cardiac Events (ALLIANCE) compared atorvastatin with usual care in 2 442 
patients with coronary heart disease.18 Atorvastatin dose was increased from 10 mg to a maximum 
of 80 mg if necessary to achieve a target LDL-C concentration of <2.1 mmol/L. The drugs received (if 
any) by the usual care group were not described. Median duration of follow up was 54.3 months. 
The hazard ratio for cardiac death, non-fatal MI, resuscitated cardiac arrest, cardiac revascularisation 
procedure or unstable angina was 0.83 (95% confidence interval 0.71 to 0.97). The Treating to New 
Targets (TNT) study compared atorvastatin 80 mg to atorvastatin 20 mg in 10 001 patients with 
coronary heart disease. Median duration of follow up was 4.9 years. The hazard ratio for coronary 
death, non-fatal MI, resuscitated cardiac arrest or stroke was 0.78 (95% confidence interval 0.69 to 
0.89). 




Three studies directly compared atorvastatin and simvastatin (the study settings and primary 
efficacy results are summarised in Table 1). Marz et al and Olsson et al compared atorvastatin and 
simvastatin in patients with existing coronary heart disease in terms of their ability to reduce LDL-C 
to below 2.6 mmol/L.19,20 In both arms drug doses were increased (if necessary) based on LDL-C 
measurements. In both studies atorvastatin resulted in a greater proportion of patients reaching 
target LDL-C concentrations. Pedersen et al compared fixed doses of atorvastatin 80 mg and 
simvastatin 20 mg in patients who had a previous myocardial infarction.21 Fewer patients had a 
major cardiovascular event in the atorvastatin arm, but the difference did not reach statistical 
significance. 
Table 1. Atorvastatin versus simvastatin for the secondary prevention of cardiovascular disease 
Study n Setting Intervention Duration  Primary outcome 
Marz et al19 3 748 Germany Atorvastatin 10–40 




67% of atorvastatin patients 
and 53% of simvastatin 
patients reached the target of 
LDL-C <2.6 mmol/L (p<0.001) 
Olsson et 
al20 










61% of atorvastatin patients 
and 42% of simvastatin 
patients reached the target of 
LDL-C <2.6 mmol/L (p<0.001) 
Pedersen et 
al21 
8 888 Northern 
Europe 
Atorvastatin 80 mg 




Hazard ratio for coronary 
death, non-fatal MI or 
resuscitated cardiac arrest of 
0.89 (95% CI 0.78 to 1.01) 
 
The benefits of statin therapy relative to no treatment have been clearly demonstrated. Higher 
doses of atorvastatin relative to lower doses further reduce cardiovascular risk. Those findings led to 
several international guidelines recommending either high dose statins (at a fixed dose), or treating 
to a lower target LDL-C concentration than those described in the studies above. The current 
European Society of Cardiology (ECS)/European Atherosclerosis Society (EAS) guidelines and South 
African Heart Association/Lipid and Atherosclerosis Society of Southern Africa guidelines 
recommend titration of statin dose to achieve LDL-C concentrations of below 1.8 mmol/L for 
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secondary prevention.10,11 Recent American College of Cardiology (ACC)/American Heart Association 
(AHA) guidelines and National Institute for Health and Care Excellence (NICE) in the United Kingdom 
guidelines recommend atorvastatin 80 mg for secondary prevention unless patients have contra-
indications to this drug or dose, or they are at an increased risk of statin side effects or drug 
interactions.12,13 They state that there is no randomised controlled trial evidence to support 
treatment to target LDL-C concentrations, and instead recommend different statin doses for patients 
at different levels of risk of cardiovascular disease.  
Local statin efficacy data 
Most of the statin randomised controlled trials described above were conducted in Europe and/or 
North America. There were 81 South African participants in the A to Z trial, and 523 in the Treating 
to New Targets trial.14,22 A PubMed search identified three randomised controlled trials that 
assessed statins exclusively in South African patients, but all those trials involved the treatment of 
familial hypercholesterolaemia (a genetic disorder that causes severe elevations in LDL-C) only.23-25 
Those studies are therefore not relevant to this analysis. 
Statins for the secondary prevention of cardiovascular disease: cost-
effectiveness 
Background: assessing cost-effectiveness of interventions 
Cost-effectiveness analyses compare health interventions in terms of both their costs and 
outcomes.26 Cost-effectiveness analyses express outcomes in natural units, such as cases prevented 
or life years gained. Cost-utility analyses express outcomes in generic units, such as life years or 
quality adjusted life years (QALYs). Determining whether or not an intervention is cost effective 
depends on willingness-to-pay thresholds relevant to the particular setting.  In cost effectiveness and 
cost utility analyses, determining cost-effectiveness involves the calculation of an incremental cost-




effectiveness ratio (ICER): the ratio of the difference in costs and the difference in outcomes 
between two interventions.27 The ICER is compared to a threshold at which the payer is assumed to 
be willing to pay the additional costs in order to gain the additional outcomes.28 The intervention is 
deemed cost-effective if it falls below the willingness-to-pay threshold. 
Like most countries, South Africa doesn’t have an explicitly stated threshold. The World Health 
Organization CHOICE (CHOosing Interventions that are Cost-Effective) guidelines suggest that an 
intervention that costs less than a country’s GDP per capita per life year gained is highly cost-
effective.29 While interventions that cost below that threshold (per outcome gained) may be 
considered cost-effective, that does not necessarily mean that the interventions are affordable, 
given the finite health care budget in the public sector. The budget impact of choosing one 
intervention over another depends on the prevalence of the condition to be treated.  There might 
also be ethical considerations in terms of resource allocation. That being said, cost-effectiveness 
analyses can be useful aids to policy-makers. The South African National Department of Health 
published guidelines for voluntary pharmacoeconomic submissions in 2013.1  
Search strategy: cost effectiveness of statin therapy for the secondary prevention of 
cardiovascular disease 
To address the objectives: 
• to describe the current available evidence regarding the cost-effectiveness of statins in the 
secondary prevention of cardiovascular disease; and 
• to summarise important methodological considerations for the conduct of a cost-effectiveness 
analysis; 
I conducted a PubMed search using the following search terms: ‘statins’, ‘cost effectiveness’, and 
‘secondary prevention’.  
The full search details were: 
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("hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological Action] OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl-coa"[All 
Fields] AND "reductase"[All Fields] AND "inhibitors"[All Fields]) OR "hydroxymethylglutaryl-coa 
reductase inhibitors"[All Fields] OR "statins"[All Fields]) AND ("cost-benefit analysis"[MeSH Terms] 
OR ("cost-benefit"[All Fields] AND "analysis"[All Fields]) OR "cost-benefit analysis"[All Fields] OR 
("cost"[All Fields] AND "effectiveness"[All Fields]) OR "cost effectiveness"[All Fields]) AND 
("secondary prevention"[MeSH Terms] OR ("secondary"[All Fields] AND "prevention"[All Fields]) OR 
"secondary prevention"[All Fields])  
Inclusion criteria 
• Types of studies: cost effectiveness or cost utility analyses.
• Population: adults with a history of cardiovascular disease (eligible for statins for secondary 
prevention of cardiovascular disease).
• Interventions: statin therapy (all statins at all doses).
• Comparators: placebo or alternative statin or dose.
• Outcomes: life years, QALYs or events averted.
• Language: full article available in English. 
The inclusion criteria were quite broad to explore the methods used and not only the interventions 
assessed. 
Eligible studies  
The search identified 178 articles.  I excluded 144 based on review of titles or abstracts. Twenty-five 
studies met the inclusion criteria. A further seven were potentially eligible but I was unable to access 
the full text articles. A further two eligible studies were identified through the reference lists of 
other studies.30,31  
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Most of the studies were conducted in North America or Europe. One was conducted in Hong 
Kong,32  one in India,33 and one in Brazil.34 The interventions were compared within secondary 
prevention patients populations: mostly based on large statin randomised controlled trials, but some 
based on risks derived from meta-analyses or cohort studies. 
Interventions and results 
Eighteen studies compared the costs and outcomes of statins versus placebo or no statin (their 
interventions and results are summarised in Table 2). The other nine compared higher dose statins 
with lower dose statins (summarised in Table 3). None of the studies compared a fixed statin dose 
with a treat to target LDL-C concentration strategy. 
It is difficult to compare the studies directly as many different strategies were compared, and many 
different outcomes were reported. Although most studies reported ICERs, they were reported in 
different currencies, and assessed in different settings, so accepted willingness to pay thresholds 
varied.  In general, authors reported that statins could be considered cost-effective when compared 
to reported ICERs for other cardiovascular interventions, or accepted willingness to pay thresholds.   
In turn, authors generally reported that higher dose statins were cost-effective relative to lower 
dose statins. Where subgroup analyses were performed, ICERs tended to be lower for groups at the 
highest risk of cardiovascular events.




Table 2. Cost-effectiveness of statins in secondary prevention of cardiovascular disease: statins compared to placebo 
Study Setting Intervention Time 
frame 
Incremental cost effectiveness ratio Assumed WTP 
threshold 
Jonsson et al30 Sweden Simvastatin 20–40 mg versus placebo 5.4 years £5 502 per life year Not stated 
Ashraf et al35 United States Pravastatin 40 mg versus placebo 10 years $7 124–12 665 per life year gained Not stated 
Johannesson et al31 Sweden Simvastatin 10–40 mg versus placebo 5 years $5 400 (men) and $10 500 (women) per life year Not stated 
Riviere et al36 Canada Simvastatin 10–40 mg versus placebo 15 years $6 108–29 888 per life year gained (depending on 
assumptions regarding duration of statin effects) 
Not stated 
Muls et al37 Belgium Pravastatin 40 mg versus placebo 10 years $13 274–24 359 per life year gained (depending on 
cardiovascular risk factors) 
$20 000 
Grover et al38 Canada Simvastatin 10–40 mg versus placebo 5.4 years $4 419–13 404 in men and $4 927–21 719 in 
women (depending on cardiovascular risk factors) 
Not stated 
Pickin et al39 United Kingdom Simvastatin 10–40 mg versus placebo Lifetime £5 100–12 500 (depending on cardiovascular risk) Not stated 
Tsevat et al40 United States Pravastatin 40 mg versus placebo Lifetime $16 000–32 000 per QALY (depending on model) Not stated 
Chau et al32 Hong Kong Pravastatin 40 mg versus placebo 5 years HK$207 151 per QALY Not stated 
Van Hout et al41 Netherlands Statin versus placebo 5 years €6 695–9 970 per life year gained  €18 000 
Schwartz et al42 United States Atorvastatin 80 mg versus placebo 16 weeks $4 086 per event avoided Not stated 
Chaplin et al43 Netherlands Fluvastatin 40 mg versus placebo 10 years €9 312 per QALY; €8 954 per life year €20 000 
Olsson et al44 Sweden Atorvastatin 80 mg versus placebo 16 weeks €1643.64 per event avoided Not stated 
Scuffham et al45 United Kingdom Fluvastatin 80 mg versus placebo 10 years £3207 per QALY £30 000 
Fidan et al46 England and 
Wales 
Statin versus no statin 10 years £4 246 per life year gained £30 000 
Kongnakorn et al47 United States Atorvastatin 80 mg versus placebo Lifetime $13 916 per QALY Not stated 
Bennet et al48 Ireland Statin versus no statin 10 years €4 340–6 982 per life year gained Not stated 
Sanmukhani et al33 India Simvastatin 40 mg versus placebo 
Pravastatin 40 mg versus placebo 
5.4 years ₹690 000 to prevent 1 major coronary event and 
₹1 690 000 to prevent 1 CHD death 
₹2 000 000 to prevent 1 event 
Not stated 
QALY: Quality Adjusted Life Year; WTP: willingness-to-pay




Table 3. Cost-effectiveness of statins in secondary prevention of cardiovascular disease: high dose statins compared to low dose statins 
Study Setting Intervention Time 
frame 
Incremental cost Assumed WTP 
threshold 
Huse et al49 United States Atorvastatin 10 mg versus simvastatin 10 mg 
Atorvastatin 10 mg versus pravastatin 20 mg 
Atorvastatin 10 mg versus lovastatin 20 mg  
Atorvastatin 10 mg versus fluvastatin 20 mg  
Lifetime Atorvastatin dominates 
Atorvastatin dominates 
Atorvastatin dominates 
$6 169–10 639 (men) & $6 122–22 512 (women) per 
life year gained, depending on cardiovascular risk 
Not stated 
Russel et al50 Canada Atorvastatin 10 mg versus simvastatin 10 mg 
Atorvastatin 10 mg versus pravastatin 20 mg 
Atorvastatin 10 mg versus lovastatin 20 mg  
Atorvastatin 10 mg versus fluvastatin 20 mg  
Lifetime Atorvastatin dominates 
Atorvastatin dominates 
Atorvastatin dominates 
CDN$9 655–18 736 (men) & CDN$12 333–45 383 









Atovastatin 80 mg versus simvastatin 20–40 
mg 
Lifetime €31 179 per QALY 
€41 381 per QALY 
€23 261 per QALY 





Mark et al52 United States Atorvastatin 80 mg versus 10 mg 5 years $8 964 to prevent one coronary artery disease 
death, non-fatal MI, resuscitation from cardiac 
arrest or stroke 
60% probability of 
cost-effectiveness 
at WTP threshold of 
$15 000 
Wagner et al53 Canada Atorvastatin 80 mg versus 10 mg Lifetime Canadian$ 11 969 per QALY (95% CI 5 469 to 40 531) Canadian$50 000 
Taylor et al54 United Kingdom 
Spain 
Germany  
Atorvastatin 80 mg versus 10 mg Lifetime €9 500 per QALY 
€21 000 per QALY 




Ara et al55 United Kingdom Atorvastatin 80 mg versus simvastatin 40 mg 
Rosuvastatin 40 mg versus simvastatin 40 mg 
Lifetime £17 469 per QALY 




Greece Rosuvastatin 40 mg versus atorvastatin 40 
mg, simvastatin 40 mg and pravastatin 40 mg 
20 
years 
Rosuvastatin dominated other treatments Not stated 
Ribeiro et al34 Brazil Low dose (simvastatin 10 mg) versus no statin 
Intermediate dose (atorvastatin 10 mg, 
simvastatin 40 mg) versus low dose 
High dose (atorvastatin 20–80 mg, 
rosuvastatin 20 mg) versus intermediate dose 
Lifetime Int$2 827 per QALY 
Int$3 526 per QALY 
 
Int$40 418 per QALY 
Int$11 770 
QALY: Quality Adjusted Life Year; WTP: willingness-to-pay




Methodology of eligible studies 
Statin efficacy estimates 
Nine studies were based directly on the efficacy results of clinical trials, and were conducted over 
the time frame of the relevant study (Table 4). Some studies extrapolated costs and clinical 
outcomes beyond the time period of the clinical trials (Table 5). Both those types of analyses were 
restricted to direct comparisons of the statins and doses that were used in clinical trials.  
Table 4. Cost-effectiveness analyses of statins in secondary prevention of cardiovascular disease: 
efficacy estimates based directly on clinical trial results 
Study Source of efficacy estimate 
Jonsson et al30 Scandinavian Simvastatin Survival Study (4S)7 
Johannesson et al31 4S study7 
Grover et al38 4S study7 
Chau et al32 Cholesterol and Recurrent Events (CARE) study9 
Van Hout et al41 CARE,9 4S7 & Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)8 
studies 
Schwartz et al Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) 
study57 
Olsson et al44 MIRACL study57 
Mark et al52 Treating to New Targets (TNT) study22 
Sanmukhani et al33 CARE,9 4S7 and LIPID8 studies 
 
Table 5. Cost-effectiveness analyses of statins in secondary prevention of cardiovascular disease: 
long term benefits extrapolated from clinical trials 
Study Source of efficacy estimate 
Ashraf et al35 Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC) I & II 
studies58,59 Framingham Heart Study60 
Riviere et al36 Scandinavian Simvastatin Survival Study (4S)7 
Muls et al37 PLAC I & II studies58,59 and Framingham Heart Study60 
Pickin et al39 4S7 and UK actuary data 
Tsevat et al40 Cholesterol and Recurrent Events (CARE) study9 
Chaplin et al43 Lescol Intervention Prevention Study (LIPS)61 
Scuffham et al45 LIPS61 
Lindgren et al51 Incremental Decrease in End points through Aggressive Lipid lowering (IDEAL) study21 
Wagner et al53 Treating to New Targets (TNT) study22 
Taylor et al54 TNT study22 
Kongnakorn et al47 Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial16 
Saskatchewan health data 
 




Several other cost effectiveness analyses compared statin effects indirectly, using data regarding the 
relative effects of statins on LDL-C and risk of cardiovascular events, to compare statins or doses not 
directly tested within a clinical trial (Table 6). Huse et al used United States Food and Drug 
Administration labelling as a source for the effects of various statins on LDL-C concentrations.49 They 
used those reductions to estimate the relative risk of cardiovascular events based on risk tables 
derived in the Framingham Heart Study.60 Russel et al used a similar method in their analysis: they 
also used Framingham Heart Study risk tables, but used the results of an eight-week clinical trial as a 
source of data for the reduction in LDL-C by various statins.50,60,62 Fidan et al and Bennet et al used 
the relative reduction in mortality rates from published clinical trials and meta-analyses to estimate 
the number of deaths prevented by statin treatment in general in the secondary prevention 
population.46,48 They did not list the specific data sources in the article, but referred readers to a 
website.63 Ara et al used data from 28 clinical trials (combined using a mixed treatment comparison 
model) to estimate the effects of various statin doses on LDL-C cholesterol.55 They then used a 
published meta-analysis as a source for the relative risk reduction of cardiovascular events 
associated with each 1 mmol/L decrease in LDL-C concentration.64 Fragoulakis used a published 
meta-analysis as a data source for the effect of various statins on LDL-C, and estimated the risks of 
cardiovascular events using a risk table calibrated to the Greek population.56,65,66 Ribeiro et al used a 
published meta-analysis of the relative risk reduction of cardiovascular effects of various statins and 
doses, grouped by their expected effect on LDL-C.34,67 The data sources for the studies that 
compared statins effects indirectly are summarised in Table 5. 
Table 6. Cost-effectiveness of statins in secondary prevention of cardiovascular disease: outcomes 
extrapolated indirectly from changes in low density lipoprotein cholesterol concentrations 
Study Source of relative risks of cardiovascular events and efficacy estimates 
Huse et al49 FDA labelling and Framingham Heart Study60 
Russel et al50 Clinical trial62 and Framingham Heart Study60 
Fidan et al46 IMPACT model63 
Bennet et al48 IMPACT model63 
Ara et al55 Mixed treatment comparison of 28 clinical trials. Meta-analysis of efficacy studies.64 
Fragoulakis et al56 Meta-analysis of statin effects.65 HellenicSCORE.66 
Ribeiro et al34 Meta-analysis of statin effects.67 Statins grouped by expected effect on LDL-C 





Most of the published economic evaluations are cost effectiveness analyses, expressing outcomes in 
natural units such as life years gained or cardiovascular events prevented (Tables 1 and 2). Several 
studies are cost utility analyses, and express outcomes in quality-adjusted life years. None of the 
studies captured quality of life data prospectively. Instead they used quality of life weighting factors 
from other published studies to estimate QALYs. 
Study perspective and costing data 
The vast majority of the economic evaluations are from the provider perspective, and estimated 
direct medical costs only, although one captured data regarding productivity losses too.51 All trials 
included the costs of the statin medication, usually derived from national formularies or 
reimbursement costs.  Many excluded other concomitant medication, on the assumption that such 
costs would be similar between the intervention groups. Some included out-patient visits and 
laboratory costs related to statin use, while others didn’t mention those intervention costs. Most 
calculated the costs of treating cardiovascular events such as myocardial infarctions or strokes using 
diagnosis related groups (DRGs) reimbursement costs. DRGs are based on healthcare resource 
utilisation and are used to calculate costs for treating illness according to many different patient 
types. DRGs are used in prospective payment systems such as Medicare in the United States. Other 
studies used costs from published studies conducted in similar settings. Sanmukhani et al included 
intervention costs only, and didn’t include the costs of treating events.33 Most of the published 
economic evaluations discounted costs and outcomes at rates of 3–5%. 
Analysis 
Most of the analyses used Markov modelling, usually over a five-year and/or lifetime timeframe, 
with annual cycles. Most calculated cost-effectiveness ratios that the authors compared to accepted 




willingness-to-pay thresholds in order to make decisions regarding the cost-effectiveness of the 
interventions assessed. 
Methodology of cost-effectiveness analyses 
My review of relevant cost-effectiveness literature identified several important considerations for 
my analysis. Firstly, to my knowledge there are no published studies that have assessed health-
related quality of life among patients with chronic cardiovascular disease in South Africa. For that 
reason, a cost-effectiveness analysis, calculating outcomes in terms of life years, was more 
appropriate than a cost-utility analysis. Secondly, there are several published cost-effectiveness 
analyses that based their efficacy estimates on indirect comparisons of statins, and conducted their 
analyses using Markov models. My analysis used this indirect approach as there are no published 
randomised controlled trials that directly compared the interventions assessed. Thirdly, as none of 
the analyses were conducted in South Africa, and I was unable to find suitable costing data (see 
below), I had to estimate the costs of treating cardiovascular events for my analysis. Finally, the 
literature search highlighted the importance of conducting sensitivity analyses in cost-effectiveness 
analyses. 
Markov models 
Markov models are used to calculate the costs and consequences of a particular intervention over 
time, and are thus particularly valuable when assessing chronic conditions such as prevention of 
myocardial infarction or strokes.68 Markov models assume patients are always in one of several 
finite, discrete, health states, for a fixed length of time – the Markov cycle. Over time, patients can 
move from one state to another: transition probabilities describe the chance of transition from one 
state to another at the end of each Markov cycle.  




Of particular relevance for this analysis, Markov models allow for the synthesis of data regarding 
costs and outcomes from various different sources.69 They also allow one to extrapolate costs and 
outcomes beyond those observed in (relatively) short clinical trials, and as well as to link 
intermediate outcomes (such as reduction in LDL-C) to final outcomes (such as death). 
Costing 
The costs that are included in a cost-effectiveness analysis depend on the perspective of the 
analysis. My analysis was conducted from the provider perspective, so I included the costs of 
cardiovascular event-related hospital admissions, as well as the costs of the interventions, only. In 
general, costs are calculated by estimating the quantity of resources consumed, and multiplying that 
by the costs of the resources.26 Microcosting, where utilisation of each resource is estimated 
individually, is considered more accurate than gross costing, which involves estimating overall costs 
per day across all patients. Tan et al (Netherlands) found microcosting to be more accurate than 
gross costing when estimating hospital admission costs for appendicectomy, normal delivery, stroke, 
and myocardial infarction.70 Heerey et al (Ireland) found microcosting to be more accurate than 
using estimates based on Diagnostic Related Groups when estimating hospital admission costs for 
myocardial infarction, cardiac failure and HIV.71 Both studies used patient utilisation data and unit 
costs to estimate costs of diagnostic tests, procedures and drugs, and used mean costs per patient 
day to estimate hotel costs (Tan et al) and nursing and medical salaries (Heerey et al). Barron and 
Monitcelli suggest estimating the mean cost per patient day by dividing the total hospital 
expenditure by the patient day equivalent, which is calculated by adding all inpatient days, half of 
day cases, and one third of outpatient visits.72 I used patient utilisation data to estimate the costs of 
drugs, diagnostic tests, and surgical procedures and used a patient day equivalent approach for staff 
salaries and hospital overhead and hotel costs. 




Uncertainty and sensitivity analyses 
Briggs identifies four main sources of uncertainty in economic evaluations: data sources and 
sampling; extrapolation of data (for example using an intermediate outcome to estimate effects on 
mortality or morbidity); methods used (for example choice of discount rate); and generalisability of 
results to other settings.73 He suggests assessing the effects on results of varying important efficacy 
and cost estimates through one-way, multiway and threshold analysis, as well as using ‘extreme 
scenario’ analyses. All of those are relevant to my analysis. 
Data sources to inform cost-effectiveness analysis: efficacy 
To my knowledge there are no randomised controlled trials that directly compare fixed statin doses 
with treating to a target cholesterol concentration. The effects of treating to target were assessed in 
several studies described above, but to my knowledge no trials have assessed the effects of treating 
to the new (lower) targets described in recent guidelines. For those reasons I used an indirect 
approach to assess the relative efficacy of the proposed strategies for my cost effectiveness analysis, 
similar to the approaches used by Ara et al, Huse et al and Russel et al (described above).49,50,55 
To find relevant data regarding the effects of statins on LDL-C and risk of cardiovascular disease, I 
conducted a PubMed search using the terms ‘statins’ and ‘low density lipoprotein cholesterol’, 
restricted to meta-analyses.   
The full search details were: 
(("hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological Action] OR 
"hydroxymethylglutaryl-coa reductase inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl-coa"[All 
Fields] AND "reductase"[All Fields] AND "inhibitors"[All Fields]) OR "hydroxymethylglutaryl-coa 
reductase inhibitors"[All Fields] OR "statin"[All Fields]) AND ("cholesterol, ldl"[MeSH Terms] OR 
("cholesterol"[All Fields] AND "ldl"[All Fields]) OR "ldl cholesterol"[All Fields] OR ("low"[All Fields] 




AND "density"[All Fields] AND "lipoprotein"[All Fields] AND "cholesterol"[All Fields]) OR "low density 
lipoprotein cholesterol"[All Fields])) AND Meta-Analysis[ptyp] 
The search identified 211 articles. Many of the studies were unsuitable for the purposes of my 
analysis as they assessed the effects of one particular statin only, or were conducted within a certain 
patient sub-population (for example patients with diabetes or renal disease). Others assessed statins 
overall, rather than by specific doses, or listed cardiovascular risk reduction by statins overall, rather 
than in the secondary prevention population. Some were completed before some of the major 
clinical trials had been published. Two were assessed as most relevant for my analysis.  
Naci et al conducted a systematic review of randomised controlled trials that compared statins with 
placebo, or with other statins, in terms of their effect on LDL-C concentrations.74 They included 181 
trials, and used a network meta-analysis to directly or indirectly compare the effects on LDL-C of all 
the statins and doses studied. They estimated that atorvastin doses greater than 40 mg resulted in a 
mean decrease in LDL-C of 1.57 mmol/L (95% credible interval 1.31 to 2.07); doses of simvastatin 
11–20 mg resulted in a mean decrease in LDL-C of 1.07 (95% credible interval 0.7 to 1.56); and doses 
of simvastatin 21–40 mg resulted in a mean decrease in LDL-C of -1.42 (95% credible interval 1.03 to 
1.91).  
The Cholesterol Treatment Trialists’ (CTT) collaboration conducted a meta-analysis of statin 
randomised controlled trials using individual patient data.75 Studies were eligible for inclusion if they 
enrolled at least 1 000 patients, and had at least two years’ duration of treatment. They estimated 
that in patients with previous coronary heart disease, the rate ratio of cardiovascular events per 
1 mmol/L reduction in LDL-C was 0.79 (95% confidence interval 0.76 to 0.82).  




Data sources to inform cost-effectiveness analysis: costs of treating 
cardiovascular events in South Africa 
I conducted a series of PubMEd searches to identify potential costing data sources for my analysis. 
Using the terms ‘cost’, ‘myocardial infarction’, and ‘South Africa’ identified 14 potential articles; and 
‘cost’, ‘stroke’, and ‘South Africa’ resulted in 65 potential articles. Similar searches using the terms 
‘unstable angina pectoris’ and ‘revascularisation procedure’ identified no articles. Three studies 
reported hospitalisation costs for myocardial infarction or stroke, but all were based on medical aid 
schemes’ data or diagnosis related groups. No studies reported costs from a public health care sector 
perspective. 
Moodley et al used a large private medical aid database to estimate mean hospitalisation costs for 
various events in patients receiving statins in 2003-2004.76 They reported mean costs of R13 513 
($1 797) for myocardial infarction, R94 237 ($12 535) for stroke, R51 317 ($6 826) for ischaemic 
heart disease, and R54 919 ($7 305) for percutaneous transluminal coronary angioplasty. Bergh et al 
(published in 2013) used medical aid claim data to estimate the median hospitalisation costs of 
strokes and myocardial infarctions to use in a cost effectiveness analysis of dabigatran.77 They 
reported a median cost of R10 156 to 39 353 ($1 045 to 4 091), depending on assumed disability 
after the stroke, and R78 869 ($8 199) for myocardial infarction). Torborg et al used a private 
medical aid scheme’s costs according to diagnosis related groups in their cost effectiveness analysis 
of post-operative troponin monitoring.78 The hospitalisation costs for a myocardial infarction ranged 
from R27 684.26 to 59 145.94 ($2 553 to 5 454). 
Summary  
Statins reduce the risk of cardiovascular events such as angina, heart attacks and strokes, by 
lowering low density lipoprotein cholesterol (LDL-C) concentrations. Several studies, mostly 




conducted in Europe or North America, have demonstrated the cost-effectiveness of statins in the 
secondary prevention of cardiovascular disease. Some guidelines recommend increasing statin doses 
until target LDL-C concentrations are achieved, while others recommend prescribing a fixed statin 
dose without monitoring LDL-C. 
Identification of areas for further research 
Despite their widespread use, there are no published cost-effectiveness analyses of statins for the 
secondary prevention of cardiovascular disease in South Africa. There are also only limited efficacy 
data from clinical trials and no costing data of cardiovascular events from a public healthcare sector 
perspective. 
Given the burden of cardiovascular disease in South Africa, it is important to establish whether 
interventions aimed at preventing cardiovascular disease are not only effective, but cost effective 
too. I estimated the costs of hospitalisation for myocardial infarctions, strokes, unstable angina 
pectoris and coronary revascularisation procedures using a sample of patients from a public sector 
hospital; and compared the costs and outcomes of prescribing statins at fixed doses versus treating 
to target LDL-C using efficacy estimates from published meta-analyses. The results might be used to 
help guide policy regarding secondary prevention of cardiovascular disease in South Africa. 
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Statins reduce the risk of cardiovascular events such as angina, heart attacks and strokes, by 3 
lowering low density lipoprotein cholesterol (LDL-C) concentrations. Some guidelines recommend 4 
increasing statin doses until target LDL-C concentrations are achieved (treat to target: TTT), while 5 
others recommend prescribing a fixed statin dose without monitoring LDL-C. Monitoring LDL-C is 6 
relatively expensive compared to the cost of statins, but there is limited evidence that it might 7 
improve adherence. We explored the cost-effectiveness of three statin prescribing strategies for the 8 
secondary prevention of cardiovascular events at a South African public sector tertiary hospital. 9 
Methods 10 
We compared the costs and outcomes (life years), from a provider perspective, of TTT, or prescribing 11 
atorvastatin 80 mg without LDL-C monitoring, with the status quo, simvastatin 20 mg without LDL-C 12 
monitoring. We constructed a Markov model with annual cycles; a five-year timeline; starting age of 13 
60 years; and the following health states: ≤1 year after first cardiovascular event, ≤1 year after 14 
subsequent cardiovascular event, >1 year after any cardiovascular event, and dead. We estimated 15 
cardiovascular event and intervention costs using hospital expenditure and utilisation records. We 16 
estimated transition probabilities using published literature. We discounted costs and outcomes at 17 
3% per year. We explored alternative scenarios and timelines in sensitivity analyses. 18 
Results 19 
Atorvastatin 80 mg without LDL-C monitoring was both the cheapest and most effective option over 20 
a five-year period. It remained the most effective option over a lifetime period, but with an 21 
incremental cost-effectiveness ratio (ICER) of $146.94 per life year gained relative to the status quo. 22 
TTT was as effective as atorvastatin 80 mg if we assumed adherence rates of 80% and 60% 23 
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respectively, but with an ICER of $54930.96. TTT would dominate atorvastin 80 mg only if the 24 
frequency of LDL-C monitoring was reduced from 3-monthly to 6-monthly until targets were 25 
reached, and the cost of LDL-C monitoring decreased by $9.25 (84%). 26 
Conclusions 27 
Fixed-dose statin treatment without cholesterol monitoring is the most cost-effective option for 28 
providing statins for the secondary prevention of cardiovascular disease. The costs of regular LDL-C 29 
monitoring currently make a treat to target strategy unaffordable in our setting.30 




The prevalence of cardiovascular disease is increasing in South Africa.[1] High serum concentrations 32 
of low density lipoprotein cholesterol (LDL-C) increase the risk of cardiovascular disease.[2, 3] Statins 33 
(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are a class of drugs that lower LDL-C 34 
concentrations by inhibiting cholesterol synthesis in the liver, and have been shown to reduce the 35 
risk of cardiovascular events such as angina, heart attacks and strokes.[4] Several different strategies 36 
for prescribing statins have been proposed. This analysis focuses on strategies proposed for the 37 
secondary prevention of cardiovascular disease; that is the prevention of further cardiovascular 38 
events in those patients who have already experienced a cardiovascular event. 39 
According to some South African and European guidelines, patients with existing atherosclerotic 40 
cardiovascular disease should start statin treatment at a dose based on their baseline LDL-C 41 
concentrations.[3, 5] LDL-C should be monitored regularly, and statin dose should be increased if 42 
necessary to achieve an LDL-C concentration <1.8 mmol/L. In contrast, guidelines from the United 43 
States and United Kingdom recommend a fixed high dose statin, namely atorvastatin 80 mg, for 44 
secondary prevention and measurement of LDL-C at baseline, at around three months after 45 
treatment initiation, and then only as indicated clinically.[6, 7]  46 
Statin drug costs are decreasing over time, but monitoring LDL-C concentrations remains relatively 47 
expensive. In addition, there is evidence that in practice clinicians rarely increase statin doses as 48 
recommended, even in settings where frequent LDL-C monitoring is standard practice.[8-11] This 49 
raises the question of whether statins could or should be prescribed at a fixed dose without LDL-C 50 
monitoring. Some authors argue that measuring LDL-C concentration is essential to ensure patients’ 51 
adherence to statin therapy, but there is little evidence to support this.[12]  52 
Current practice at Groote Schuur Hospital, a public sector tertiary hospital in Cape Town, South 53 
Africa is to prescribe a fixed dose of simvastatin 20 mg, with LDL-C measured at baseline only (along 54 
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with a full screening lipogram to exclude familial hypercholesterolaemia), with no further LDL-C 55 
monitoring. This analysis explores the cost-effectiveness of prescribing statins according to LDL-C 56 
concentrations, or prescribing a high dose statin without LDL-C monitoring, relative to the status 57 
quo. 58 
Methods 59 
Study design 60 
We conducted a cost-effectiveness analysis from a public sector provider perspective. We compared 61 
the costs and outcomes (in terms of life years) of simvastin 20 mg, atorvastatin 80 mg (both without 62 
cholesterol monitoring) and adjusting statin doses based on cholesterol concentration for the 63 
secondary prevention of cardiovascular events using a Markov model. We estimated cardiovascular 64 
event costs using an ingredients approach as well as allocation of costs according to inpatient days. 65 
We estimated transition probabilities using published literature. Strategies were compared using an 66 
incremental cost-effectiveness ratio and those showing higher costs and lower effectiveness than an 67 
alternative were eliminated through absolute dominance. All costs were expressed in 2012 prices, 68 
converted to United States (US) dollars using an average 2012 exchange rate of $0,12227/R1.[13] 69 
We discounted costs and outcomes at 3% per year. 70 
Population 71 
The study population comprises patients requiring secondary prevention of cardiovascular events at 72 
Groote Schuur Hospital. 73 
Interventions 74 
The status quo comprises simvastatin 20 mg daily, regardless of cholesterol concentration, with a 75 
baseline lipogram, but no further cholesterol monitoring. The atorvastatin arm comprises 76 
atorvastatin 80 mg daily, also with a baseline lipogram but no further cholesterol monitoring (a ‘fire-77 
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and-forget’ approach). In the treat-to-target arm, patients have a baseline lipogram and LDL-C 78 
monitoring and dose changes based on the following assumptions. A literature search revealed no 79 
published data regarding the baseline LDL-C concentrations of the population served by Groote 80 
Schuur Hospital. But in a cohort of 2 182 patients at Chris Hani Baragwanath Hospital in 81 
Johannesburg, baseline LDL-C concentrations were between 2.4–3.0 mmol/L depending on 82 
ethnicity.[14] So for the purposes of this analysis we assumed that everyone would start at 83 
simvastatin 20 mg (10–20 mg is recommended for those baseline concentrations).[3] A local 84 
guideline recommends measuring LDL-C concentrations every 8±4 weeks, and increasing statin dose 85 
if the target concentration is not reached.[3] While several local (and international) studies have 86 
shown that only around 10–50% of patients achieve target concentrations at those low doses, in 87 
practice, patients tend to stay on their starting dose, rather than having their doses increased.[8-11, 88 
15] We assumed a best-case scenario, where concentrations not at target resulted in a dose increase 89 
according to recommendations. We conservatively assumed that 50% of patients had their dose 90 
increased to simvastatin 40 mg after 3 months of treatment, then 50% of those patients had a 91 
further dose increase, to atorvastatin 80 mg, at 6 months. The proportion of patients at the various 92 
doses then remained unchanged for subsequent model cycles (i.e. 50% on simvastatin 20 mg; 25% 93 
on simvastatin 40 mg; and 25% on atorvastatin 80 mg). We explored alternative prescribing 94 
scenarios in sensitivity analyses. 95 
Costs of cardiovascular events 96 
We estimated the costs of treating myocardial infarction, unstable angina, coronary 97 
revascularisation procedures and strokes using a sample of patients from Groote Schuur Hospital.  98 
We included all adult (>18 years) patients with relevant ICD10 codes or procedures (coronary artery 99 
bypass grafts or percutaneous transluminal coronary angioplasty), who were admitted between 01 100 
January 2012 and 31 December 2013, and spent at least one night in a hospital ward. Some patients 101 
were admitted more than once during the period. During the two-year sampling period, 1 604 102 
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patients were admitted with relevant ICD10 diagnoses or procedures. We excluded five who were 103 
<18 years old; 31 with missing age data; and 14 with missing ward stay or cost centre data.  Patient 104 
and admission numbers and characteristics are shown in Table 1. 105 
Table 1: Characteristics according to diagnosis of 1 554 patients during 1 797 admissions to a South 








Patients     
n 434 586 182 519 
Age, years (median (IQR)) 59 (50–67) 57 (49–64) 58 (52–64) 51 (40–64) 
Male (n (%)) 282 (65) 362 (62) 131 (72) 233 (45) 
Admissions     
n 446 630 183 538 
Length of stay, days (mean 
(95% CI)) 
4.2  
(3.8 to 4.6) 
4.9  
(4.4 to 5.4) 
12.3  
(10.7 to 13.9) 
13.1  
(12.2 to 13.9) 
CI: confidence interval; IQR: interquartile range 
We used all sample patients to estimate health services utilisation using hospital expenditure 106 
records, and calculated costs using 2012 prices or hospital expenditure. We estimated the mean 107 
costs of laboratory tests, drugs, blood products and diagnostic and surgical procedures per inpatient 108 
day, then multiplied those costs by the mean length of stay to estimate the mean cost of admission 109 
for each of the cardiovascular events. We obtained the prices of drugs, laboratory investigations, 110 
and blood products from hospital expenditure records. We estimated the costs of diagnostic 111 
investigations (such as xrays, CT scans and ECGs) and surgical procedures using the Uniform Patient 112 
Fee Schedule, which lists fees to be paid by private patients at public sector facilities.[16] 113 
We calculated overall hospital overhead costs such as utilities (water, electricity, sewerage), 114 
catering, housekeeping, security, hospital management and administrative staff salaries, doctor 115 
salaries, and general maintenance using routine hospital accounting data. We assumed that all 116 
patients, regardless of diagnosis, consumed roughly the same amount of overhead resources. 117 
Following the standard approach in this setting, we calculated a patient day equivalent for Groote 118 
Schuur Hospital by adding all the inpatient days, half of the day cases and one third of the outpatient 119 
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visits over the time period, and divided the total cost by the patient day equivalent, to estimate the 120 
cost per patient day equivalent. [17] We used a similar method to allocate ward costs, which 121 
comprised consumables, nurses’ salaries, and certain ‘ward stock’ drug costs which are allocated by 122 
ward, rather than to specific patients. Mean hospitalisation costs for each cardiovascular event are 123 
shown in Table 2. 124 
Based on published estimates we assumed that 50% of stroke-related deaths and 30% of coronary 125 
heart disease-related deaths occurred in hospital.[18-26] We included the costs of in-hospital 126 
deaths, but not those deaths that occurred out of hospital. We also did not include costs of deaths 127 
due to other causes.  128 
We used Microsoft Excel and Stata 13.0 for data management and cost calculations.[27]129 
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Table 2. Mean hospitalisation costs according to diagnosis at a South African public sector tertiary hospital in 2012 United States dollars 
Cost category Myocardial infarction Unstable angina Coronary revascularisation 
procedures 
Stroke 
 Inpatient day Admission Inpatient day Admission Inpatient day Admission Inpatient day Admission 
Hospital 158.22 659.78 158.22 773.70 158.22 1950.86 158.22 2069.53 
Ward 231.71 966.23 226.03 1105.28 251.54 3101.53 279.81 3659.93 
Surgical procedures 218.02 909.14 275.35 1346.47 302.35 3727.92 27.68 362.10 
Diagnostic procedures 46.38 193.42 39.78 194.51 28.73 354.24 108.19 1415.18 
Laboratory investigations 30.94 129.00 26.65 130.34 24.98 307.99 10.29 134.64 
Drugs 9.47 39.46 3.76 18.38 1.49 18.42 5.26 68.85 
Blood products 12.98 54.14 16.43 80.36 61.69 760.62 2.87 37.49 
Total 707.72 2951.17 746.22 3649.03 829.00 10221.59 592.33 7747.72 
130 
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Intervention costs 131 
The costs associated with providing statins according to the status quo include: the annual cost of 132 
simvastatin 20 mg; one lipogram at baseline only (first year); and two outpatient visits per year. The 133 
costs associated with providing statins according to the ‘fire and forget’ strategy include: the annual 134 
cost of atorvastatin 80 mg; one lipogram at baseline only (first year); and two outpatient visits per 135 
year. The costs associated with providing statins according to the ‘treat to target’ strategy include: 136 
annual drug costs (according to the proportion of patients expected to be receiving each statin 137 
dose), regular LDL-C monitoring, and clinic visits. Treat to target guidelines recommend 3 monthly 138 
monitoring until patients are at target, followed by 6 monthly monitoring. As described above, we 139 
assumed that 50% of patients would reach their target LDL-C concentration by 3 months, and a 140 
further 25% by 6 months. This results in a mean of 2.75 clinic visits and LDL-C measurements in the 141 
first year, and two per year thereafter.  We calculated clinic overhead and consumable costs using 142 
Groote Schuur Hospital expenditure and utilisation data as described above for hospitalisation costs. 143 
The unit costs of the drugs, outpatient visits, and laboratory monitoring are shown in Table 3. 144 
Table 3. Costs of providing statins for secondary prevention of cardiovascular events at a South 
African public sector tertiary hospital in 2012 United States dollars  
Outpatient visit  
Cardiac or general medicine clinic 105.48 
Annual drug costs  
Simvastatin 20 mg  8.27 
Simvastatin 40 mg  16.23 
Atorvastatin 80 mg  79.53 




Markov model 145 
We constructed a Markov model with the following health states: alive in the first year of treatment; 146 
alive in subsequent years of treatment; alive within one year of myocardial infarction; alive within 147 
one year of unstable angina pectoris; alive within one year of stroke; alive within one year of 148 
Cost-effectiveness of statin prescribing strategies for secondary prevention                                            Manuscript 
11 
 
coronary revacularisation procedure; and death (Figure 1). We used a five-year timeline with a 149 
starting age of 60 years, and cycles of one year. We used TreeAge Pro 2015 software for the cost-150 
effectiveness analysis.[28] 151 
 
Figure 1. Simplified Markov model states and transitions.  
Dashed lines indicate the occurrence of a cardiovascular event. Cardiovascular events comprise 
myocardial infarction, unstable angina pectoris, stroke, or coronary revascularisation procedure. 
 
Transition probabilities 152 
We estimated the effects of statin treatment by multiplying the risk reduction of major 153 
cardiovascular events associated with each statin dose by the expected annual incidence of those 154 
events in patients who are not on statins. Data regarding the incidence of those events in South 155 
Africa are extremely limited.  International cohort studies generally recruit patients who are already 156 
on statins. For those reasons we estimated the annual incidences (in those not on statins) of 157 
myocardial infarction, unstable angina pectoris, stroke, and coronary revascularisation procedures, 158 
as well as cardiovascular mortality, from the placebo groups of three large international clinical trials 159 
Alive ≤1 year after 
first cardiovascular 
event
Alive >1 year after 
cardiovascular 
event
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of statins in patients with existing cardiovascular disease, with follow up periods of around five years 160 
(Table 4).  We estimated age-specific mortality from other causes by subtracting cardiovascular and 161 
cerebrovascular deaths from overall deaths using published South African mortality tables.[29] Naci 162 
et al conducted a network meta-analysis of 181 randomised controlled trials to estimate the average 163 
effect on LDL-C concentrations of various statins at various doses.[30] The Cholesterol Treatment 164 
Trialists’ Collaboration conducted a meta-analysis of 26 randomised controlled trials to estimate the 165 
average risk reduction per 1 mmol/L reduction in LDL-C overall and for various patient subgroups.[4] 166 
They estimated a risk reduction of 0.79 for major cardiovascular events in those patients with 167 
existing cardiovascular disease.  We used those two meta-analyses to estimate the risk reduction 168 
associated with the three statin doses in our analysis (Table 5). 169 
Table 4. Annual transition probabilities in patients with existing cardiovascular disease 
Event Transition probability Reference 
Myocardial infarction 0.016 [31-33] 
Unstable angina pectoris 0.038 [32, 33] 
Stroke 0.007 [31-33] 
Coronary revascularisation procedure 0.030 [31-33] 
Cardiovascular death 0.017 [31, 33] 
Cerebrovascular death 0.011 [31, 33] 
Death – other causes Varies by age [29] 
 
 
Table 5. Risk reduction of cardiovascular events by statins 
Statin Effect on  
LDL-C[30] 
RR1 per 1 mmol/L 
decrease[4] 
Rate ratio 
Simvastatin 20 mg -1.07 0.79 0.7753 
Simvastatin 40 mg -1.42 0.79 0.7018 
Atorvastatin 80 mg -1.57 0.79 0.6703 
1. Rate ratio 
We used estimated transition probabilities for one-year outcomes after cardiovascular events from 170 
various sources (Table 6). The outcomes are for those already on statin treatment, and for the 171 
purposes of our analysis are the same for all treatment groups. As for the incidence of events, South 172 
African data regarding outcomes after events are extremely limited. Wagner et al listed outcomes 173 
after events from the Treating to New Targets clinical trial, which compared atorvastatin 10 and 174 
80 mg.[34] Data from this trial are appropriate for our analysis as the trial population comprised 175 
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patients with existing cardiovascular disease, and all trial patients received statin treatment.[35] In 176 
addition, 523 (of 10 001) participants were South African. The authors report that probabilities of 177 
outcomes after events were similar across treatment groups, so we did not adjust the probabilities 178 
according to intervention group.  Schamroth et al reported outcomes after myocardial infarction and 179 
unstable angina pectoris from 615 South African patients in the ACCESS (Acute Coronary Events – a 180 
Multinational Survey of Current Management Strategies) registry.[36]   We estimated stroke 181 
mortality using two South African public-sector studies.[37, 38]  We estimated  mortality after 182 
revascularisation procedures using rates reported by Jones et al from the United Kingdom.[39] 183 
Table 6. Transition probabilities: one-year outcomes after events 
Outcomes after events One-year rates References 
Myocardial infarction   
Myocardial infarction 0.0489 [34, 35] 
Unstable angina pectoris 0.0890 [36] 
Stroke 0.0147 [34, 35] 
Revascularisation procedure 0.3961 [34, 35] 
All-cause mortality 0.0670 [36] 
Unstable angina pectoris   
Myocardial infarction 0.0109 [36] 
Unstable angina pectoris 0.0890 [36] 
Stroke 0.0109 [36] 
Revascularisation procedure 0.5000 [36] 
All-cause mortality 0.0500 [36] 
Stroke   
Myocardial infarction 0.0191 [34, 35] 
Stroke 0.0813 [34, 35] 
Revascularisation procedure 0.0335 [34, 35] 
All-cause mortality 0.2500 [37, 38] 
Revascularisation procedure   
Myocardial infarction 0.0270 [34, 35] 
Stroke 0.0105 [34, 35] 
Revascularisation procedure 0.1349 [34, 35] 
All-cause mortality 0.0539 [39] 
 
Sensitivity analysis 184 
The main sources of uncertainty in this analysis relate to the assumptions made regarding statin 185 
dose increases in the treat-to-target intervention arm and the generalisability of the results. We 186 
conducted threshold and multivariate sensitivity analyses to assess the robustness of the cost-187 
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effectiveness estimates and to explore alternative scenarios. The base case assumes 100% 188 
adherence for all interventions. It has been proposed that the treat to target strategy results in 189 
better adherence than fixed doses of statins. The sensitivity analyses also explored different 190 
proportions of adherence for the alternative secondary prevention strategies.  191 
Results 192 
Costs, outcomes and cost-effectiveness 193 
The costs, outcomes, and incremental cost effectiveness ratios (ICERs) of the three interventions are 194 
shown in Table 7. The three interventions were similar in terms of life years gained. Atorvastatin 195 
80 mg was the most effective and the cheapest strategy, so dominated both the status quo, and the 196 
treat to target strategy.  197 
Table 7. Costs, outcomes and cost-effectiveness ratios of three strategies for prescribing statins for 
the secondary prevention of cardiovascular disease at a South African public sector tertiary 
hospital 
 Cost Life years ICER 
Simvastatin 20 mg $3924.19 4.32 Dominated 
Treat to target $4044.80 4.33 Dominated 
Atorvastatin 80 mg $3877.44 4.34  
ICER: incremental cost effectiveness ratio 
Sensitivity analyses 198 
The results did not change significantly when we changed the discount rate from 0 to 6%, or when 199 
we estimated event costs using the upper and lower limits of the 95% confidence intervals of the 200 
length of stay estimates. Atorvastatin 80 mg was still the most effective strategy when we extended 201 
the model to a lifetime timeline. It still dominated treat to target, but had an ICER of $146.94 relative 202 
to the status quo. In a lifetime timeline atorvastatin would dominate simvastatin 20 mg at a 203 
reduction in annual drug cost of $3.66 (a 5% reduction in 2012 prices). Assuming 80% adherence for 204 
the treat to target strategy and 60% for the others resulted in equivalent outcomes for treat to 205 
target and atorvastatin 80 mg, but treat to target was much more expensive. Changing the 206 
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proportions of patients on various statin doses in the treat to target intervention did not significantly 207 
change the results: treat to target was dominated by atorvastatin 80 mg even if we assumed that all 208 
patients were on atorvastatin 80 mg or all patients were on simvastatin 20 mg. If we assumed all 209 
patients were on atorvastatin 80 mg, and treat to target was associated with 80% adherence and 210 
atorvastin 80 mg (without LDL-C monitoring) was associated with 60% adherence, treat to target 211 
resulted in slightly better outcomes than atorvastatin (4.33 life years versus 4.31), with an ICER of 212 
$11 641.67. Treat to target was dominated by atorvastatin 80 mg even if the costs of measuring LDL-213 
C were assumed to be zero. This is because the relatively high costs of the extra clinic visits needed 214 
in the treat to target strategy aren’t offset by the costs saved by the reduction in cardiovascular 215 
events. The only scenario where treat to target was both more effective and cheaper than 216 
atorvastatin was if clinic visits were reduced to two in the first year (which is less than that 217 
recommended in some current guidelines), and the price of measuring LDL-C concentration 218 
decreased to $1.71 (an 84% reduction in the 2012 price).  219 
Table 8. Sensitivity analyses: costs, outcomes and cost-effectiveness ratios of three strategies for 
prescribing statins for the secondary prevention of cardiovascular disease  
   Cost Life years ICER 
Discount rate 0% Simvastatin 20 mg $4164.15 4.56 dominated 
 Treat to target $4286.19 4.57 dominated 
 Atorvastatin 80 mg $4113.77 4.59  
Discount rate 6% Simvastatin 20 mg $3710.21 4.10 dominated 
 Treat to target $3829.54 4.11 dominated 
 Atorvastatin 80 mg $3666.73 4.12  
Length of stay:  Simvastatin 20 mg $3588.99 4.32 dominated 
Lower limit of  Treat to target $3725.57 4.33 dominated 
95% CI Atorvastatin 80 mg $3583.33 4.34  
Length of stay: Simvastatin 20 mg $4402.35 4.32 dominated 
Upper limit of  Treat to target $4366.95 4.33 dominated 
95% CI Atorvastatin 80 mg $4536.86 4.34  
Lifetime timeline Simvastatin 20 mg $10888.26 11.37  
 Treat to target $11128.53 11.49 dominated 
 Atorvastatin 80 mg $10930.94 11.66 $146.94 
Adherence 60% Simvastatin 20 mg $3922.43 4.30 dominated 
                     60% Atorvastatin 80 mg $3928.43 4.31  
                     80% Treat to target $4118.98 4.31 $54930.96 
CI: confidence interval; ICER: incremental cost effectiveness ratio 




Our analysis of three statin prescribing strategies for the secondary prevention of cardiovascular 221 
disease demonstrated that atorvastatin 80 mg without LDL-C monitoring, was both the cheapest and 222 
most effective option in our setting over a five-year period. It remained the most effective option 223 
over a lifetime period, but with an ICER of $146.94 relative to the status quo (simvastatin 20 mg 224 
without LDL-C monitoring). Treating to a target LDL-C concentration would be more effective and 225 
cheaper than atorvastin 80 mg only if the number of clinic visits for each intervention were the 226 
same, and the cost of LDL-C monitoring decreased by $9.25 (84%). 227 
The relatively low rates of cardiovascular events in the population we used in this analysis (in the 228 
absence of data from South Africa) resulted in only small differences between the three 229 
interventions that we compared in terms of outcomes. But the relatively high costs of cholesterol 230 
monitoring and clinic visits resulted in large differences in terms of costs. The fact that atorvastatin 231 
80 mg dominated simvastatin 20 mg over five years, but had a relatively small ICER over a lifetime is 232 
probably due to the fact that death from cardiovascular disease becomes a relatively smaller 233 
proportion of overall deaths as the rate of death from other causes rises with age. This essentially 234 
means that in our model statins become relatively less effective at preventing death over time. 235 
South African pharmacoeconomic guidelines do not specify a cost-effectiveness threshold below 236 
which interventions can be considered to be cost-effective.[40] World Health Organization CHOICE 237 
suggests that interventions can be considered very cost-effective at ICERs less than a country’s per 238 
capita gross domestic product (GDP), and cost-effective at ICERs less than three times GDP.[41] 239 
South Africa’s 2012 GDP per capita was US$7 590,03.[42] Therefore atorvastatin 80 mg could be 240 
considered very cost-effective even over a lifetime time period. However, treat to target could not 241 
be considered cost-effective, even if we assumed that adherence was improved by regular 242 
monitoring of LDL-C cholesterol concentrations. 243 
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Some authors have suggested that regular cholesterol monitoring is essential to ensure adherence 244 
to statin therapy. Wei et al used a United Kingdom record linkage database analysis to show that 245 
patients requiring statins for secondary prevention who were treated using a treat to target 246 
approach were 1.87 (95% confidence interval 1.58 to 2.22) times more likely to be at least 80% 247 
adherent than those treated according to a fire and forget approach.[12] To our knowledge this 248 
retrospective observational study is the only published attempt to address the question. It remains a 249 
potential area for further research, but the cost of frequent cholesterol monitoring currently makes 250 
a treat to target strategy unaffordable in most resource-limited settings. 251 
While several previous studies have shown statins to be cost-effective at various doses, to our 252 
knowledge only one study (a systematic review and meta-analysis) has compared different 253 
monitoring strategies, but the comparison was essentially between frequency of monitoring within a 254 
treat to target strategy. Perera et al found annual lipid monitoring to be cost effective relative to 255 
three-yearly monitoring, assuming that abnormal concentrations resulted in starting statins or 256 
increasing statin dose in all cases.[43]  257 
Our study has several strengths, most notably the fact that to our knowledge this is the first 258 
thorough costing of cardiovascular events in the public healthcare sector in South Africa. However, 259 
there are several limitations. We had to use indirect comparisons for statin efficacy, as there are no 260 
clinical trials that directly compared the three interventions of interest. This indirect approach to 261 
estimate relative efficacy has been used before,[44-46] but obviously a direct comparison would be 262 
ideal. We did not compare other possible interventions (atorvastatin 40 mg for example) as we 263 
based the interventions on recommendations in current international guidelines. However, our 264 
indirect comparison approach means that our model is flexible enough to be used to make multiple 265 
further comparisons in the future. We were not able to estimate the costs of treating potential statin 266 
side effects, so those costs were not included in our model. We also did not account for potential 267 
differences in tolerability between high dose atorvastatin and simvastatin. As high dose atorvastatin 268 
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might be associated with relatively more patients stopping treatment because of side effects, we 269 
might have overestimated the effectiveness of atorvastatin. We assumed that adherence was 270 
constant over time, but in practice there would likely be attrition over time in all groups. Our 271 
analysis is based on a tertiary hospital population, which limits the generalisability of our results. The 272 
vast majority of patients who require secondary prevention are actually treated at a primary health 273 
care level, where treatment costs (specifically clinic visit costs) are likely to be cheaper. However, 274 
those costs are the same for all interventions, so the cost-effectiveness rankings are unlikely to be 275 
different in different settings, although the lifetime costs and ICERs would change. 276 
Conclusions 277 
Our study shows that statin treatment without cholesterol monitoring is currently the most cost-278 
effective option in our setting.  279 
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Statins for the secondary prevention of 
cardiovascular disease: cost-effectiveness 
of prescribing strategies in the South 




Statins are an important public health intervention as they reduce the risk of cardiovascular 
events such as angina, heart attacks and strokes. But statin prescribing guidelines vary, even 
within South Africa. We explored the cost-effectiveness of three statin prescribing strategies for 
the secondary prevention of cardiovascular events at a South African public sector tertiary 
hospital. This policy brief outlines our methods and key findings.
Introduction
Cardiovascular disease prevalence is increasing in 
South Africa.1 It is important to reduce the risk of 
cardiovascular events such as angina, heart 
attacks, and strokes in order to limit morbidity and 
mortality. From a public healthcare provider 
perspective, reducing cardiovascular risk also 
reduces the significant costs associated with 
hospitalisations for cardiovascular events. 
Patients who have already experienced a 
cardiovascular event are at increased risk of a 
further event, so local and international guidelines 
agree that they should all receive statins (unless 
contraindicated). However, guidelines disagree on 
the best way to prescribe statins: some 
recommend monitoring low density lipoprotein 
cholesterol (LDL-C) regularly and increasing statin 
doses until target LDL-C concentrations are 
achieved, while others recommend prescribing a 
fixed statin dose without monitoring LDL-C.2-5
Statin drug costs are decreasing over time, but 
monitoring LDL-C concentrations remains 
relatively expensive. Some authors argue that 
measuring LDL-C concentration is essential to 
ensure patients’ adherence to statin therapy, but 
there is little evidence to support this. 
Research question
Our analysis compared the costs, from a provider 
perspective, and life years gained of:
• simvastatin 20 mg, with a lipogram (to exclude 
familial hypercholesterolaemia) at baseline 
only, with no further LDL-C monitoring 
(current practice);
• atorvastatin 80 mg, also with a baseline 
lipogram but no further monitoring; and
• starting simvastatin 20 mg then measuring 
LDL-C 3-monthly and increasing statin dose 
until target concentrations are reached, then 
measuring LDL-C 6-monthly (treat to target),
at Groote Schuur Hospital, Cape Town, South 
Africa.
Key messages
• High LDL-C concentrations increase the risk of 
cardiovascular disease
• Statins lower LDL-C and reduce the risk of 
cardiovascular disease
• Prescribing statins at a fixed high dose is more 
effective, and relatively less expensive, than 
treating to a target LDL-C concentration
Markov model
Markov models are used to estimate the costs and 
outcomes of interventions over time, and are 
particularly valuable when assessing chronic 
conditions such as cardiovascular disease. Markov 
models assume patients are always in one of 
several discrete health states, for a fixed length of 
time – the Markov cycle. At the end of each 
Markov cycle patients can move from one state to 
another. The probabilities of moving from one 
state to another (or staying in the same state for 
the next Markov cycle) are known as transition 
probabilities.
We constructed a Markov model with annual 
cycles; a five-year timeline; starting age of 60 
years; and the following health states: ≤1 year 
after first cardiovascular event, ≤1 year after 
subsequent cardiovascular event, >1 year after 
any cardiovascular event, and dead (Figure 1). 
Figure 1. Markov model states and transitions. Dashed 
lines indicate the occurrence of a cardiovascular event. 
Definitions and terms
Cardiovascular event: myocardial infarction, 
unstable angina pectoris, coronary 
revascularisation procedure (coronary artery 
bypass grafts or percutaneous transluminal 
coronary angioplasty) or stroke.
Secondary prevention: the prevention of further 
cardiovascular events in those patients who have 
already experienced a cardiovascular event.
LDL-C: a type of cholesterol that causes plaque 
deposits in arteries, which can lead to 
cardiovascular events.
Statin: (3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitor) a class of drugs that reduce 
serum LDL-C concentrations by inhibiting 
cholesterol synthesis in the liver.
Lipogram: a laboratory blood test that measures 
total cholesterol, LDL-C, high density lipoprotein 
cholesterol and triglycerides. It is used to screen 
for diseases where ‘standard’ statin prescribing 
strategies might not be suitable.
Incremental cost effectiveness ratio: the 
additional cost per life year gained by one 
intervention compared to another.
Transition probabilities
No trial has directly compared the three proposed 
interventions, so we estimated the effects of 
statin treatment by multiplying the risk reduction 
of major cardiovascular events associated with 
each statin dose by the expected annual incidence 
of those events in patients who are not on statins. 
We estimated the annual incidences of 
cardiovascular events and cardiovascular mortality 
from published literature, as we could find no data 
specific to the South African population.6-8 We 
estimated risk reduction for each statin dose using 
two meta-analyses: one which estimated the 
average effect on LDL-C concentrations of various 
statin doses; and one which estimated the average 
risk reduction per 1 mmol/L reduction in LDL-C.9,10
Figure 2 illustrates the effects of statin treatment 
that we used to calculate the transition 
probabilities for cardiovascular events in our 
model. 
We used estimated transition probabilities for 
one-year outcomes after cardiovascular events 
from several published studies.11-16 We estimated 
age-specific mortality from other causes using 
published South African mortality tables.17
Figure 2. Effects of statin treatment on the risk of 
cardiovascular events in patients who have already 
had a cardiovascular event.
Costs
Cardiovascular events
We used hospital expenditure records for 1 554 
patients admitted for cardiovascular events during 
2012 and 2013 to estimate mean utilisation of 
laboratory tests, diagnostic and surgical 
procedures, drugs and blood products. We 
obtained the prices of drugs, laboratory 
investigations, and blood products from hospital 
expenditure records. We estimated the costs of 
diagnostic investigations (such as xrays, CT scans 
and ECGs) and surgical procedures using the 
Uniform Patient Fee Schedule, which lists fees to 
be paid by private patients at public sector 
facilities.18 We calculated overall hospital overhead 
costs such as utilities (water, electricity, sewerage), 
catering, housekeeping, security, staff salaries, and 
general maintenance using routine hospital 
accounting data. We calculated a patient day 
equivalent by adding all the inpatient days, half of 
the day cases and one third of the outpatient visits 
over the time period, and divided the total cost by 
the patient day equivalent, to estimate 
hospitalisation cost per patient day equivalent.19
We multiplied those costs by the mean length of 
stay to calculate overall admission costs (Figure 3). 
All costs were expressed in 2012 prices, converted 
to United States (US) dollars using an average 2012 
exchange rate of $0,12227/R1.20
Intervention costs
Intervention costs comprise drug costs, outpatient 
visits (calculated using hospital data as described 
for hospitalisation costs above), and the costs of 
measuring LDL-C. Each intervention also included a 
baseline lipogram. In the treat to target 
intervention we assumed that all patients would 
start at simvastatin 20 mg; 50% of patients would 
have a dose increase to simvastatin 40 mg at three 
months; and a further 25% would have a dose 
increase to atorvastatin 80 mg at six months. 
Figure 4 illustrates statin treatment costs.
Figure 3. Mean hospitalisation costs according to 
cardiovascular event in 2012 United States dollars 
Figure 4. Mean costs of statin treatment for a five year 
period in 2012 United States dollars.
Results
Atorvastatin 80 mg without LDL-C monitoring, was both the cheapest and most effective option over a 
five-year period. The interventions resulted in similar outcomes of 4.32, 4.33 and 4.34 life years, with costs 
of $3 924.19, $4 044.80 and $3 877.44 respectively for simvastatin 20 mg, treat to target and atorvastatin. 
Atorvastatin 80 mg was also the most effective option when we ran the analysis over a lifetime period, but 
had an incremental cost-effectiveness ratio of $146.94 per life year gained relative to the simvastatin 
20 mg. It would be more effective and cheaper than simvastatin 20 mg over a lifetime period if its price 
decreased by 5%. 
Treat to target was as effective as atorvastin 80 mg if we assumed adherence rates of 80% and 60% 
respectively, but with an ICER of $54 930.96. Changing the proportions of patients on various statin doses 
in the treat to target intervention did not significantly change the results: treat to target was more 
expensive and less effective than atorvastatin 80 mg even if we assumed that all patients had their doses 
increased to atorvastatin 80 mg or all patients remained on simvastatin 20 mg.
Policy implications
World Health Organization CHOICE suggests that 
interventions can be considered cost-effective at 
ICERs less than three times a country’s per capita 
gross domestic product (GDP).21 South Africa’s 
2012 GDP per capita was US$7590.22 Therefore 
atorvastatin 80 mg could be considered very 
cost-effective even over a lifetime period. 
However treat to target could not be considered 
cost-effective, even if we assumed that 
adherence was improved by regular monitoring 
of LDL-C cholesterol concentrations.
Our analysis is based on a tertiary hospital 
population, but outpatient costs are the same for 
all interventions, so intervention rankings are 
unlikely to be different in different settings, 
although the overall costs and ICERs would 
change.
In addition to being the most cost-effective 
option, prescribing statins without regular 
monitoring could have other potential benefits 
for the health system. Patients could attend 
clinics less frequently, and doctor or nurse 
consultation time saved by not monitoring 
could be used for other health promotion 
activities such as educating patients regarding 
diet or screening for other cardiovascular risk 
factors.
Conclusions
Fixed-dose statin treatment without cholesterol 
monitoring is the most cost-effective option for 
providing statins for the secondary prevention 
of cardiovascular disease. The costs of regular 
LDL-C monitoring currently make a treat to 
target strategy unaffordable in our setting. 
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